News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Doris Makari

Articles by Doris Makari

105 Real-World Overall Survival With Palbociclib Plus an Aromatase Inhibitor (AI) in Overweight/Obese Patients With HR+/HER2− Metastatic Breast Cancer (MBC)

ByAdam M. Brufsky, MD, PhD,Neil M. Iyengar, MD,Xianchen Liu,Benjamin Li,Doris Makari,Lynn McRoy,Aaron B. Cohen,Melissa Estevez,Vandana G. Abramson,Rachel M. Layman,Giuseppe Curigliano

May 18th 2026

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

ByHeather Moore,Avirup Guha,Doris Makari,Rachael McCaleb,Irene Arias,Stella Stergiopoulos,Benjamin Li,Michael Fradley,Susan Dent, MD

July 25th 2024

Latest Updated Articles

Trending on CancerNetwork

Generic Enzalutamide Receives Tentative FDA Approval in Prostate Cancer

Teclistamab Induction Shows Feasibility in Transplant-Eligible Myeloma

ASCO Breakthrough 2026 Wrap-Up: Precision Oncology, AI, and Biomarkers Define the Future of Cancer Care

ASCENT-07 and Triple-Negative Breast Cancer Advances

Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines